-
公开(公告)号：US09771579B2
公开(公告)日：2017-09-26
申请号：US13805745
申请日：2011-06-23
IPC分类号： C12N15/11 , C12N15/113 , A61K31/7088 , C12Q1/68
CPC分类号： C12N15/113 , A61K31/7088 , C12N15/1138 , C12N2310/111 , C12N2310/113 , C12N2310/315 , C12Q1/6813 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
-
公开(公告)号：US20130245099A1
公开(公告)日：2013-09-19
申请号：US13988063
申请日：2011-11-17
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K31/00 , A61K31/7088 , A61K31/7115 , C12N15/111 , C12N2310/113 , C12N2310/3231 , C12N2310/3341 , C12N2310/344 , C12N2310/321 , C12N2310/3521 , C12N2310/111 , C12N2330/10
摘要： Provided herein are compositions, compounds, and methods of modulating gene expression. In certain embodiments described herein is a composition, wherein the composition comprises an antagoNAT. In some embodiments, the antagoNAT is an oligonucleotide comprising modified and unmodified sugar subunits, wherein the antagoNAT hybridizes with a natural antisense transcript. Certain embodiments of the present invention provide a method for modulating gene expression in a cell comprising contacting the cell with an antagoNAT. In some embodiments, the method includes forming a hybrid comprising the antagoNAT and a natural antisense transcript of the gene, wherein the hybrid sterically blocks the normal function of the natural antisense transcript.
摘要翻译： 本文提供调节基因表达的组合物，化合物和方法。 在本文所述的某些实施方案中是组合物，其中所述组合物包含antagoNAT。 在一些实施方案中，antagoNAT是包含修饰和未修饰的糖亚基的寡核苷酸，其中antagoNAT与天然反义转录物杂交。 本发明的某些实施方案提供了调节细胞中基因表达的方法，包括使细胞与antagoNAT接触。 在一些实施方案中，所述方法包括形成包含所述基因的antagoNAT和天然反义转录物的杂种，其中所述杂合物空间阻断天然反义转录物的正常功能。
-
3.发明申请TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1 审中-公开通过抑制自然抗原转录到SIRT1来治疗SIRTUIN 1（SIRT1）相关疾病公开(公告)号：US20110319317A1
公开(公告)日：2011-12-29
申请号：US13254600
申请日：2010-03-03
IPC分类号： A61K31/713 , A61P35/00 , A61P25/28 , A61P25/14 , A61P25/16 , A61P25/00 , A61P21/00 , A61P3/00 , A61P5/50 , A61P3/10 , A61P3/04 , A61P3/08 , A61P7/00 , A61P3/06 , A61P19/10 , A61P35/02 , A61P1/16 , A61P25/32 , A61P31/14 , A61P27/02 , A61P9/10 , A61P9/04 , A61P1/04 , A61P29/00 , A61P1/00 , A61P19/04 , A61P19/02 , A61P11/00 , A61Q19/08 , A61P13/00 , A61P17/00 , C12N5/071 , C12Q1/68 , C07H21/02
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12Y305/01098
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.
摘要翻译： 本发明涉及调节Sirtuin 1（SIRT1）的表达和/或功能的反义寡核苷酸，特别是通过靶向Sirtuin 1（SIRT1）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与SIRT1表达相关的疾病和病症中的用途。
-
4.发明申请TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA 有权通过抑制自然抗原转录物到SCNA，治疗钠通道，电压门控，ALPHA亚型（SCNA）相关疾病公开(公告)号：US20130096183A1
公开(公告)日：2013-04-18
申请号：US13805745
申请日：2011-06-23
IPC分类号： C12N15/113 , C12Q1/68
CPC分类号： C12N15/113 , A61K31/7088 , C12N15/1138 , C12N2310/111 , C12N2310/113 , C12N2310/315 , C12Q1/6813 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
摘要翻译： 本发明涉及调节钠通道，电压门控α亚基（SCNA）的表达和/或功能的反义寡核苷酸，特别是通过靶向钠通道，电压门控的α亚基（SCNA）的天然反义多核苷酸 ）。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与SCNA表达相关的疾病和病症中的用途。
-
5.发明申请TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1 审中-公开通过抑制自然抗原转录到SIRTUIN 1来治疗SIRTUIN 1（SIRT1）相关疾病公开(公告)号：US20110237649A1
公开(公告)日：2011-09-29
申请号：US13132987
申请日：2009-12-02
IPC分类号： A61K31/711 , C12N5/071 , C07H21/04 , C07H21/02 , A61K31/7105 , G01N33/48 , A61P35/00 , A61P31/18 , A61P9/10 , A61P25/16 , A61P25/28 , A61P35/02 , A61P3/10 , A61P1/00 , A61P17/00 , A61P25/02 , A61P3/04 , A61P13/00
CPC分类号： A61K31/712 , C12N15/1137 , C12N2310/11 , C12Y305/01098 , Y10T436/143333
摘要： Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.
摘要翻译： 寡核苷酸化合物调节Sirtuin 1（SIRT1）多核苷酸及其编码产物的表达和/或功能。 用于治疗与沉默调节蛋白1（SIRT1）相关的疾病的方法包括给患者施用一种或多种设计用于抑制SIRT1天然反义转录物的寡核苷酸化合物。
-
公开(公告)号：US10000752B2
公开(公告)日：2018-06-19
申请号：US13988063
申请日：2011-11-17
IPC分类号： C12N15/11 , C12N15/113 , A61K31/00 , A61K31/7088 , A61K31/7115
CPC分类号： C12N15/113 , A61K31/00 , A61K31/7088 , A61K31/7115 , C12N15/111 , C12N2310/113 , C12N2310/3231 , C12N2310/3341 , C12N2310/344 , C12N2310/321 , C12N2310/3521 , C12N2310/111 , C12N2330/10
摘要： Provided herein are compositions, compounds, and methods of modulating gene expression. In certain embodiments described herein is a composition, wherein the composition comprises an antagoNAT. In some embodiments, the antagoNAT is an oligonucleotide comprising modified and unmodified sugar subunits, wherein the antagoNAT hybridizes with a natural antisense transcript. Certain embodiments of the present invention provide a method for modulating gene expression in a cell comprising contacting the cell with an antagoNAT. In some embodiments, the method includes forming a hybrid comprising the antagoNAT and a natural antisense transcript of the gene, wherein the hybrid sterically blocks the normal function of the natural antisense transcript.
-
7.发明授权Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) 有权通过抑制天然反义转录物到沉默调节蛋白（SIRT）来治疗沉默调节蛋白（SIRT）相关疾病公开(公告)号：US09089588B2
公开(公告)日：2015-07-28
申请号：US13695801
申请日：2011-01-13
IPC分类号： C12N15/11 , C12N5/00 , A61K31/7088 , C12N15/113
CPC分类号： C12N15/1137 , A61K31/7088 , C12N15/113 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
摘要翻译： 本发明涉及调节Sirtuin（SIRT）表达和/或功能的反义寡核苷酸，特别是通过靶向Sirtuin（SIRT）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与Sirtuins（SIRT）表达相关的疾病和病症中的用途。
-
公开(公告)号：US20130072421A1
公开(公告)日：2013-03-21
申请号：US13695801
申请日：2011-01-13
IPC分类号： A61K31/7088 , A61P9/10 , A61P31/18 , A61P1/16 , A61P3/04 , A61P3/10 , A61P3/06 , A61P1/04 , A61P7/00 , A61P17/08 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P25/28 , A61P25/02 , A61P17/00 , A61P35/00 , A61P35/02 , A61P27/02 , A61K38/14 , C07K2/00 , C07H21/04 , A61P21/00 , A61P3/00 , A61P29/00 , A61P25/32 , A61P27/12 , A61P1/00 , A61P11/00 , A61P13/00 , C07H21/02 , C12N5/071
CPC分类号： C12N15/1137 , A61K31/7088 , C12N15/113 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
-
9.发明授权Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) 有权通过抑制胰岛素基因（INS）的天然反义转录物治疗胰岛素基因（INS）相关疾病公开(公告)号：US09234199B2
公开(公告)日：2016-01-12
申请号：US13388767
申请日：2010-08-05
IPC分类号： C07H21/04 , A61K48/00 , A61K31/7088 , C12N15/113 , A61K31/713
CPC分类号： C12N15/1136 , A61K31/713 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12Q1/6883 , C12Q2600/136 , G06F19/22
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Insulin Gene (INS).
摘要翻译： 本发明涉及调节胰岛素基因（INS）表达和/或功能的反义寡核苷酸，特别是通过靶向胰岛素基因（INS）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与胰岛素基因（INS）表达相关的疾病和病症中的用途。
-
10.发明授权Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA 有权通过抑制天然反义转录物到MSRA，治疗甲硫氨酸亚砜还原酶a（MSRA）相关疾病公开(公告)号：US08980858B2
公开(公告)日：2015-03-17
申请号：US13699356
申请日：2011-05-25
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04 , A61K31/713 , C12N9/02 , C12N15/113
CPC分类号： C12N15/1137 , A61K31/713 , C12N9/0051 , C12N15/113 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2310/315 , C12N2330/10 , C12Y108/04011
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
摘要翻译： 本发明涉及通过靶向甲硫氨酸亚砜还原酶A（MSRA）的天然反义多核苷酸来调节甲硫氨酸亚砜还原酶A（MSRA）的表达和/或功能的反义寡核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与MSRA表达相关的疾病和病症中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
92 条记录 (耗时 0.037 秒)
